Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available
MWN-AI** Summary
Siemens Healthineers has announced the launch of its Brain Health Research Portfolio, which includes new biomarker assays designed to advance the understanding of neurological diseases, particularly Alzheimer's. By introducing the Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays for research use, the company is aiming to provide scientists with vital tools for studying brain function and the progression of neurodegenerative diseases. These innovative blood tests offer a less invasive alternative to traditional cerebrospinal fluid testing, making it easier for both patients and clinicians to participate in neurodegenerative disease research.
Every year, nearly 10 million new dementia cases are reported globally, with Alzheimer's disease accounting for 60-70% of these cases. The new assays utilize chemiluminescent immunoassays to measure biomarkers in blood samples, offering high sensitivity and reliability for detecting neurological conditions. This advancement aligns with the increasing need for efficient diagnostic methods as the societal implications of neurodegenerative disorders continue to grow.
Siemens Healthineers is also involved in multiple collaborative research initiatives, including studies with organizations like the Banner Sun Health Research Institute and the PREDICTOM project, to validate the clinical utility of new biomarkers in diverse patient populations. Beyond the pTau217 and BDTau assays, the company is developing additional biomarkers, including Apolipoprotein E-?4 (ApoE-?4), potentially enhancing the landscape of blood testing in neurology.
This launch symbolizes Siemens Healthineers' commitment to providing accessible and innovative healthcare solutions, targeting underserved communities and tackling significant health challenges on a global scale.
MWN-AI** Analysis
Siemens Healthineers' recent launch of its brain health research portfolio, featuring the Atellica IM Phosphorylated tau 217 (pTau217) and Brain Derived Tau (BDTau) assays, signifies a pivotal advancement in the neurodegenerative disease landscape. As nearly 10 million new dementia cases emerge globally each year, the timely introduction of these blood-based biomarker tests is likely to enhance the early detection and management of Alzheimer's disease, a significant contributor to this increasing incidence.
From an investment perspective, this innovation positions Siemens Healthineers favorably within the expanding market for diagnostic tools in neurology. The transition from invasive lumbar punctures to less invasive blood tests will not only improve patient comfort but also broaden the scope for regular monitoring and research. The Atellica platform's established presence in laboratories provides a strategic advantage, enabling quicker adoption and scalability of these assays.
Moreover, the ongoing collaborations with prominent research institutions signal a robust commitment to scientific validation, bolstering the credibility and potential market penetration of these assays. As the focus on neurodegenerative diseases intensifies, particularly given their societal impact, Siemens Healthineers is poised to capture a significant share of a lucrative market.
Investors should closely monitor Siemens Healthineers' clinical trial outcomes and the expanding suite of biomarkers, including the anticipated Apolipoprotein E-?4 assay. Positive results could catalyze growth, driving stock performance and enhancing market confidence.
Overall, Siemens Healthineers appears to be strategically positioned to leverage its innovations in brain health diagnostics amidst rising demand. Given the aging population and corresponding healthcare challenges, long-term ownership in Siemens Healthineers may align well with growth-focused investment strategies in the biotech and healthcare sectors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Tarrytown, New York, USA, March 18, 2026 (GLOBE NEWSWIRE) --
- Research assays help generate evidence about whether biomarkers can advance disease management
- Novel RUO tests can help scientists understand neurological function and disease progression
- Collaborative research is underway to translate scientific discovery into actionable evidence
Siemens Healthineers announced today its offerings for brain health research are expanding, with the brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research use1. Every year, there are nearly 10 million new cases of dementia diagnosed worldwide2. Alzheimer’s disease is the most common, contributing to 60–70% of cases, though it affects many more people over time as these individuals become adversely impacted and increasingly dependent on others for their care2.
The blood tests from Siemens Healthineers offer researchers chemiluminescent immunoassays to provide a quantitative measurement of brain-derived phosphorylated tau 217 (p-tau217) and Brain Derived Tau (BD tau) and are run on the widely installed Atellica Solution IM and Atellica CI Analyzers. Blood-based biomarker testing offers a less-invasive method compared to cerebrospinal fluid which requires a lumbar puncture.
“Siemens Healthineers is laser focused on expanding researchers’ access to blood testing that can reduce the burden of invasive testing to better understand these diseases and help address the growing societal impact of neurodegenerative conditions,” said Jim Freeman, head of Core Laboratory Solutions R&D for Diagnostics at Siemens Healthineers. “Our Atellica IM instrument enables the high sensitivity required to detect neurological biomarkers in blood.”
“Analyzer engineering is very important for amplifying the signal we need to achieve reliable results using blood tests,” said Henrik Zetterberg, MD, PhD, an internationally renowned neuroscientist known for his pioneering research on biomarkers of Alzheimer’s disease and other neurodegenerative disorders. “Blood tests are much easier for both patients and doctors—you can scale testing, follow patients, or perhaps prepare a biomarker portfolio.”
Contributions to scientific innovation
Siemens Healthineers is involved in several research collaborations to advance earlier detection and characterization of neurological diseases with p-tau217 and BD tau biomarkers3-5. Notably, multi-cohort research studies are underway with PREDICTOM, ACCESS-AD, and Banner Sun Health Research Institute.
“We value the opportunity to work with the leading diagnostics companies to advance the fight against Alzheimer’s disease, and this is a great example,” said Nicholas Ashton, PhD, senior director of the Fluid Biomarker Program at Banner Sun Health Research Institute in Arizona. "We're working to validate the clinical utility of the plasma p-tau217 biomarker across diverse patient populations to advance early detection of Alzheimer's disease. Our findings appear to support the promise of this Alzheimer’s blood biomarker in the clinical setting. We look forward to further advancing this research.”
Other brain health biomarkers
In addition to the Atellica IM pTau217 and Atellica IM BDTau RUO assays, Siemens Healthineers offers a Neurofilament Light Chain assay (with CE mark)6 to help predict the risk of future Multiple Sclerosis disease activity. Development efforts are underway to offer additional biomarkers, including Apolipoprotein E-?4 (ApoE-?4), a protein involved in the metabolism of fats and a subtype that is implicated in Alzheimer's disease and cardiovascular diseases. Researchers can stay updated about these offerings here.
1 For research use only. Not for use in diagnostic procedures. These assays are intended to support scientific investigation and are not cleared or approved for clinical decision?making.
2 World Health Organization Dementia Fact Sheet
3 Siemens Healthineers Co-Leads EU Alzheimer’s Disease Care Initiative
4 Oberstein, T. (2026, March) Brain-derived pTau217 in plasma outperforms pTau217 and brain-derived tau assays for identifying Alzheimer´s disease (A+T1+) in MCI/mild dementia, [E-poster presentation]. AD/PD. Copenhagen, Denmark.
5 Prediction of Alzheimer’s disease using an AI driven screening platform
6 CE0197. Available for Research Use Only in the U.S.
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.
Contact Info
Kimberly Nissen
kimberly.nissen@siemens-healthineers.com
+1 610-241-2129
Attachments
FAQ**
How will Siemens Healthineers AG SEMHF's new Atellica IM pTau2and BDTau assays impact early detection and management of Alzheimer’s disease in Tarrytown, NY, especially considering the rising global incidence of dementia?
What collaborative initiatives or partnerships in Tarrytown are potentially leveraging Siemens Healthineers AG SEMHF's blood-based biomarker testing to enhance neurological research and patient care?
In what ways can the community in Tarrytown benefit from the advancements in blood testing technology for Alzheimer’s disease, as provided by Siemens Healthineers AG SEMHF, including reduced invasive procedures for patients?
What role does Siemens Healthineers AG SEMHF anticipate playing in local research collaborations focused on neurodegenerative diseases in Tarrytown, especially with regard to ongoing studies like PREDICTOM and ACCESS-AD?
**MWN-AI FAQ is based on asking OpenAI questions about Siemens Healthineers AG (OTC: SEMHF).
NASDAQ: SEMHF
SEMHF Trading
0.86% G/L:
$42.875 Last:
4,474 Volume:
$42.4375 Open:
